James G Beeson is an expert in Infectiology at Burnet Institute (Australia). James G Beeson has authored 350 publications, the most recent in 2026, and is an investigator in 7 clinical trials. SLR score: 1,171 (community average: 125). How the SLR is computed.

LeadR Profile

James G Beeson Burnet Institute Australia
1 171 ScienceLeadR Reputation 1171
Network Map

Infectiology

Subspecialties: Immunology - Pediatrics

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1993 - 2026

Source: PubMed

Burnet Institute

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 350

Citations

Citations: 18 061 1st author: 39 Last author: 104 Unique author: 5


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Targeting a malaria merozoite surface protein with mRNA vaccine generates multifunctional antibodies.
PMID 42818794 — malaria, merozoites, vaccines, antibodies, sporozoites, rna, messenger, phagocytosis, immune system diseases, immunity, alleles, complement system proteins, membrane proteins
Front Immunol20261
Protective immunity to clinical malaria is modified by the genetic diversity of P. falciparum antigens.
PMID 42700822 — genetic variation, malaria, bacterial infections, immunity, communicable diseases
J Infect20260
An abundant merozoite surface protein of Plasmodium falciparum modulates susceptibility to inhibitory antibodies.
PMID 42504823 — malaria, merozoites, vaccines, antibodies, microbiology, parasites, membrane proteins, communicable diseases, vaccine development
Elife20260
First exposure to SARS-CoV-2 shapes IgG subclass switching after mRNA vaccination.
PMID 42343025 — sars-cov-2, vaccines, antibodies, rna, messenger, vaccination, immunity, severe acute respiratory syndrome-related coronavirus, history, infections
Commun Med (Lond)20260
Antibody fine specificity correlates with protection from malaria for the RTS,S vaccine in young African children: A post hoc analysis of a phase IIb randomised controlled trial.
PMID 42133737 — malaria, antibody formation, epitopes, malaria vaccines, vaccines, antibodies, amino acids, amino acid sequence, child
PLoS Med20260

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 3 3
N/A 2
Phase 1/Phase 2 1
Phase 2 1

By status:

Completed 5
Active not recruiting 2

By type:

Interventional 7

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 1
multicentric5to9 0
multicentricup10 0

Main Topics

LeadR Networks

Main global connection map